The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Cytomegalovirus (CMV) Vaccine-Global Market Insights and Sales Trends 2024
Synopsis
Cytomegalovirus (CMV) also known as HCMV, or Human Herpesvirus 5 (HHV-5) is the virus most commonly transmitted to a developing fetus. It is a common virus that infects people of all ages. According to the CDC, over half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms. Whereas when a baby is born with cytomegalovirus (CMV) infection, it is called congenital CMV. Each year, approximately 5,000 infants in the U.S. may develop permanent problems due to CMV, some of the severe problems, includes deafness, blindness, and mental retardation. Furthermore, the global prevalence of congenital cytomegalovirus is said to be 0.3 – 2.0%. The Institute of Medicine (IOM) of the National Academy of Sciences, has designated CMV as a “highest priority” category for vaccine development, citing the years of life and disability that could be saved.
The global Cytomegalovirus (CMV) Vaccine market size is expected to reach US$ 205.9 million by 2029, growing at a CAGR of 4.4% from 2023 to 2029. The market is mainly driven by the significant applications of Cytomegalovirus (CMV) Vaccine in various end use industries. The expanding demands from the Laboratories, Hospitals, Diagnostic Centers and Clinics and Others, are propelling Cytomegalovirus (CMV) Vaccine market. Attenuated Vaccines, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Subunit Vaccines segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cytomegalovirus (CMV) Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cytomegalovirus (CMV) Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cytomegalovirus (CMV) Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cytomegalovirus (CMV) Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cytomegalovirus (CMV) Vaccine covered in this report include Merck, AlphaVax, Moderna and Novartis, etc.
The global Cytomegalovirus (CMV) Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
AlphaVax
Moderna
Novartis
Global Cytomegalovirus (CMV) Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cytomegalovirus (CMV) Vaccine market, Segment by Type:
Attenuated Vaccines
Subunit Vaccines
Global Cytomegalovirus (CMV) Vaccine market, by Application
Laboratories
Hospitals
Diagnostic Centers and Clinics
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Cytomegalovirus (CMV) Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Cytomegalovirus (CMV) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Cytomegalovirus (CMV) also known as HCMV, or Human Herpesvirus 5 (HHV-5) is the virus most commonly transmitted to a developing fetus. It is a common virus that infects people of all ages. According to the CDC, over half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms. Whereas when a baby is born with cytomegalovirus (CMV) infection, it is called congenital CMV. Each year, approximately 5,000 infants in the U.S. may develop permanent problems due to CMV, some of the severe problems, includes deafness, blindness, and mental retardation. Furthermore, the global prevalence of congenital cytomegalovirus is said to be 0.3 – 2.0%. The Institute of Medicine (IOM) of the National Academy of Sciences, has designated CMV as a “highest priority” category for vaccine development, citing the years of life and disability that could be saved.
The global Cytomegalovirus (CMV) Vaccine market size is expected to reach US$ 205.9 million by 2029, growing at a CAGR of 4.4% from 2023 to 2029. The market is mainly driven by the significant applications of Cytomegalovirus (CMV) Vaccine in various end use industries. The expanding demands from the Laboratories, Hospitals, Diagnostic Centers and Clinics and Others, are propelling Cytomegalovirus (CMV) Vaccine market. Attenuated Vaccines, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Subunit Vaccines segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cytomegalovirus (CMV) Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cytomegalovirus (CMV) Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cytomegalovirus (CMV) Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cytomegalovirus (CMV) Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cytomegalovirus (CMV) Vaccine covered in this report include Merck, AlphaVax, Moderna and Novartis, etc.
The global Cytomegalovirus (CMV) Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
AlphaVax
Moderna
Novartis
Global Cytomegalovirus (CMV) Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cytomegalovirus (CMV) Vaccine market, Segment by Type:
Attenuated Vaccines
Subunit Vaccines
Global Cytomegalovirus (CMV) Vaccine market, by Application
Laboratories
Hospitals
Diagnostic Centers and Clinics
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Cytomegalovirus (CMV) Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Cytomegalovirus (CMV) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Cytomegalovirus (CMV) Vaccine Market Overview
1.1 Cytomegalovirus (CMV) Vaccine Product Overview
1.2 Cytomegalovirus (CMV) Vaccine Market Segment by Type
1.2.1 Attenuated Vaccines
1.2.2 Subunit Vaccines
1.3 Global Cytomegalovirus (CMV) Vaccine Market Size by Type
1.3.1 Global Cytomegalovirus (CMV) Vaccine Market Size Overview by Type (2018-2029)
1.3.2 Global Cytomegalovirus (CMV) Vaccine Historic Market Size Review by Type (2018-2023)
1.3.3 Global Cytomegalovirus (CMV) Vaccine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Cytomegalovirus (CMV) Vaccine Sales Breakdown by Type (2018-2023)
1.4.2 Europe Cytomegalovirus (CMV) Vaccine Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Cytomegalovirus (CMV) Vaccine Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Cytomegalovirus (CMV) Vaccine Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales Breakdown by Type (2018-2023)
2 Global Cytomegalovirus (CMV) Vaccine Market Competition by Company
2.1 Global Top Players by Cytomegalovirus (CMV) Vaccine Sales (2018-2023)
2.2 Global Top Players by Cytomegalovirus (CMV) Vaccine Revenue (2018-2023)
2.3 Global Top Players by Cytomegalovirus (CMV) Vaccine Price (2018-2023)
2.4 Global Top Manufacturers Cytomegalovirus (CMV) Vaccine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Cytomegalovirus (CMV) Vaccine Market Competitive Situation and Trends
2.5.1 Cytomegalovirus (CMV) Vaccine Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Cytomegalovirus (CMV) Vaccine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cytomegalovirus (CMV) Vaccine as of 2022)
2.7 Date of Key Manufacturers Enter into Cytomegalovirus (CMV) Vaccine Market
2.8 Key Manufacturers Cytomegalovirus (CMV) Vaccine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Cytomegalovirus (CMV) Vaccine Status and Outlook by Region
3.1 Global Cytomegalovirus (CMV) Vaccine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Cytomegalovirus (CMV) Vaccine Historic Market Size by Region
3.2.1 Global Cytomegalovirus (CMV) Vaccine Sales in Volume by Region (2018-2023)
3.2.2 Global Cytomegalovirus (CMV) Vaccine Sales in Value by Region (2018-2023)
3.2.3 Global Cytomegalovirus (CMV) Vaccine Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Cytomegalovirus (CMV) Vaccine Forecasted Market Size by Region
3.3.1 Global Cytomegalovirus (CMV) Vaccine Sales in Volume by Region (2024-2029)
3.3.2 Global Cytomegalovirus (CMV) Vaccine Sales in Value by Region (2024-2029)
3.3.3 Global Cytomegalovirus (CMV) Vaccine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Cytomegalovirus (CMV) Vaccine by Application
4.1 Cytomegalovirus (CMV) Vaccine Market Segment by Application
4.1.1 Laboratories
4.1.2 Hospitals
4.1.3 Diagnostic Centers and Clinics
4.1.4 Others
4.2 Global Cytomegalovirus (CMV) Vaccine Market Size by Application
4.2.1 Global Cytomegalovirus (CMV) Vaccine Market Size Overview by Application (2018-2029)
4.2.2 Global Cytomegalovirus (CMV) Vaccine Historic Market Size Review by Application (2018-2023)
4.2.3 Global Cytomegalovirus (CMV) Vaccine Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Cytomegalovirus (CMV) Vaccine Sales Breakdown by Application (2018-2023)
4.3.2 Europe Cytomegalovirus (CMV) Vaccine Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Cytomegalovirus (CMV) Vaccine Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Cytomegalovirus (CMV) Vaccine Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales Breakdown by Application (2018-2023)
5 North America Cytomegalovirus (CMV) Vaccine by Country
5.1 North America Cytomegalovirus (CMV) Vaccine Historic Market Size by Country
5.1.1 North America Cytomegalovirus (CMV) Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Cytomegalovirus (CMV) Vaccine Sales in Volume by Country (2018-2023)
5.1.3 North America Cytomegalovirus (CMV) Vaccine Sales in Value by Country (2018-2023)
5.2 North America Cytomegalovirus (CMV) Vaccine Forecasted Market Size by Country
5.2.1 North America Cytomegalovirus (CMV) Vaccine Sales in Volume by Country (2024-2029)
5.2.2 North America Cytomegalovirus (CMV) Vaccine Sales in Value by Country (2024-2029)
6 Europe Cytomegalovirus (CMV) Vaccine by Country
6.1 Europe Cytomegalovirus (CMV) Vaccine Historic Market Size by Country
6.1.1 Europe Cytomegalovirus (CMV) Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Cytomegalovirus (CMV) Vaccine Sales in Volume by Country (2018-2023)
6.1.3 Europe Cytomegalovirus (CMV) Vaccine Sales in Value by Country (2018-2023)
6.2 Europe Cytomegalovirus (CMV) Vaccine Forecasted Market Size by Country
6.2.1 Europe Cytomegalovirus (CMV) Vaccine Sales in Volume by Country (2024-2029)
6.2.2 Europe Cytomegalovirus (CMV) Vaccine Sales in Value by Country (2024-2029)
7 Asia-Pacific Cytomegalovirus (CMV) Vaccine by Region
7.1 Asia-Pacific Cytomegalovirus (CMV) Vaccine Historic Market Size by Region
7.1.1 Asia-Pacific Cytomegalovirus (CMV) Vaccine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Cytomegalovirus (CMV) Vaccine Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Cytomegalovirus (CMV) Vaccine Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Cytomegalovirus (CMV) Vaccine Forecasted Market Size by Region
7.2.1 Asia-Pacific Cytomegalovirus (CMV) Vaccine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Cytomegalovirus (CMV) Vaccine Sales in Value by Region (2024-2029)
8 Latin America Cytomegalovirus (CMV) Vaccine by Country
8.1 Latin America Cytomegalovirus (CMV) Vaccine Historic Market Size by Country
8.1.1 Latin America Cytomegalovirus (CMV) Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Cytomegalovirus (CMV) Vaccine Sales in Volume by Country (2018-2023)
8.1.3 Latin America Cytomegalovirus (CMV) Vaccine Sales in Value by Country (2018-2023)
8.2 Latin America Cytomegalovirus (CMV) Vaccine Forecasted Market Size by Country
8.2.1 Latin America Cytomegalovirus (CMV) Vaccine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Cytomegalovirus (CMV) Vaccine Sales in Value by Country (2024-2029)
9 Middle East and Africa Cytomegalovirus (CMV) Vaccine by Country
9.1 Middle East and Africa Cytomegalovirus (CMV) Vaccine Historic Market Size by Country
9.1.1 Middle East and Africa Cytomegalovirus (CMV) Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Cytomegalovirus (CMV) Vaccine Forecasted Market Size by Country
9.2.1 Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Merck
10.1.1 Merck Company Information
10.1.2 Merck Introduction and Business Overview
10.1.3 Merck Cytomegalovirus (CMV) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Merck Cytomegalovirus (CMV) Vaccine Products Offered
10.1.5 Merck Recent Development
10.2 AlphaVax
10.2.1 AlphaVax Company Information
10.2.2 AlphaVax Introduction and Business Overview
10.2.3 AlphaVax Cytomegalovirus (CMV) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 AlphaVax Cytomegalovirus (CMV) Vaccine Products Offered
10.2.5 AlphaVax Recent Development
10.3 Moderna
10.3.1 Moderna Company Information
10.3.2 Moderna Introduction and Business Overview
10.3.3 Moderna Cytomegalovirus (CMV) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Moderna Cytomegalovirus (CMV) Vaccine Products Offered
10.3.5 Moderna Recent Development
10.4 Novartis
10.4.1 Novartis Company Information
10.4.2 Novartis Introduction and Business Overview
10.4.3 Novartis Cytomegalovirus (CMV) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Novartis Cytomegalovirus (CMV) Vaccine Products Offered
10.4.5 Novartis Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Cytomegalovirus (CMV) Vaccine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Cytomegalovirus (CMV) Vaccine Industrial Chain Analysis
11.4 Cytomegalovirus (CMV) Vaccine Market Dynamics
11.4.1 Cytomegalovirus (CMV) Vaccine Industry Trends
11.4.2 Cytomegalovirus (CMV) Vaccine Market Drivers
11.4.3 Cytomegalovirus (CMV) Vaccine Market Challenges
11.4.4 Cytomegalovirus (CMV) Vaccine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Cytomegalovirus (CMV) Vaccine Distributors
12.3 Cytomegalovirus (CMV) Vaccine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
